Yayu Zhong, MD
Neurology · Atlanta, GANPI 1962907998
Payments from drug & device makers
Across 122 payments — averaging $22.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$346
- AbbVie$310
- AstraZeneca$271
- Novartis$249
- Otsuka America Pharmaceutical, Inc.$182
- SK Life Science, Inc.$168
- plus $1K from 24 others
What the payments were for
- Food & beverage$2,796100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 13 | $346 |
| AbbVie | 16 | $310 |
| AstraZeneca | 10 | $271 |
| Novartis | 20 | $249 |
| Otsuka America Pharmaceutical, Inc. | 7 | $182 |
| SK Life Science, Inc. | 5 | $168 |
| Biogen | 7 | $147 |
| Pfizer | 5 | $115 |
| Lilly USA, LLC | 5 | $107 |
| Argenx US, Inc. | 3 | $86 |
| Neurocrine Biosciences, Inc. | 3 | $85 |
| Sanofi | 2 | $73 |
| Eisai Inc. | 3 | $63 |
| Johnson & Johnson | 2 | $58 |
| Cycle Pharmaceuticals Inc | 2 | $56 |
| Vanda Pharmaceuticals Inc. | 2 | $52 |
| EMD Serono, Inc. | 2 | $51 |
| Neuropace, Inc. | 1 | $51 |
| Axsome Therapeutics, Inc. | 2 | $49 |
| Azurity Pharmaceuticals, Inc. | 2 | $35 |
| TG Therapeutics, Inc. | 1 | $33 |
| ANI Pharmaceuticals, Inc. | 1 | $32 |
| Acorda Therapeutics, Inc | 1 | $29 |
| Lundbeck LLC | 1 | $29 |
| Alnylam Pharmaceuticals Inc. | 1 | $29 |
| Acadia Pharmaceuticals Inc | 1 | $22 |
| Scilex Pharmaceuticals Inc. | 1 | $19 |
| Forte Bio-pharma LLC | 1 | $18 |
| Amneal Pharmaceuticals LLC | 1 | $16 |
| Kyowa Kirin, Inc. | 1 | $13 |
How this compares
$2,796 in reported general payments places this provider in the 55th percentile of 506 neurology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 42 | $568 |
| Oxcarbazepine | 12 | $489 |
| Levetiracetam | 14 | $472 |
| Donepezil Hcl | 47 | $347 |
| Pregabalin | 15 | $345 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 20 | $178 |
Paid to pharmacies, not to this prescriber.
Other neurology in Atlanta
- James LahAtlanta$6.8M
- Jonathan GlassAtlanta$5.1M
- Allan LeveyAtlanta$4.2M
- Ben ThrowerAtlanta$3.7M
- Jeffrey EnglishAtlanta$3.1M
- Dennis LaceyAtlanta$2.8M
- Julio FlaminiAtlanta$1.6M
- Joash LazarusAtlanta$1.4M
- Frank BerensonAtlanta$1.2M
- Stewart FactorAtlanta$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.